Roche gifts blockbuster cancer drug to Galecto for new clinical partnership trial
![Hans Schambye, CEO at Galecto Biotech and chair at Danish Bio | Photo: Henriette Dan Bonde / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13426619.ece/ALTERNATES/schema-16_9/doc7i8np6wi1xjy80622wn.jpg)
The Danish-Swedish firm Galecto Biotech, which is spearheded by President and CEO Hans Schambye, has entered into a partnership with one of the giants of the pharmaceutical industry.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Galecto begins third phase II trial
For subscribers